博济医药科技股份有限公司 2022 年第一季度报告全文 证券代码：300404 证券简称：博济医药 公告编号：2022-038 博济医药科技股份有限公司 2022 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不 存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度 报告中财务信息的真实、准确、完整。 3.第一季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 74,184,304.67 | 55,245,275.36 | 34.28% | | 归属于上市公司股东的净利润（元） | 12,461,872.32 | 7,369,156 ...

博济医药科技股份有限公司 2021 年年度报告全文 博济医药科技股份有限公司 2021 年年度报告 2022 年 04 月 1 所有董事均已出席了审议本报告的董事会会议。 博济医药科技股份有限公司 2021 年年度报告全文 1、政策变化风险。我国新药研发行业相关政策波动性较大，未来若 NMPA 的新药审批要求更加严格、新药审批的节奏变化或相关政策发生较大改变，将 影响医药企业的新药研发投入及药品注册申报进度，进而影响本公司的业务开 展和营业收入。鉴于此，公司将根据相关政策法规的变化，利用公司全流程"一 站式"服务的独特优势，合理调整公司的业务结构和发展方向，加强内部培训和 人才储备，除积极承接现阶段增速较快一致性评价业务外，将充分利用公司行 业经验和人才优势，大力发展创新药临床承接业务、大力发展临床前承接业务， 增强公司抵御风险的能力。2、合同执行过程的风险。新药研发是一项高技术、 多学科的复杂系统工程，公司部分一致性评价业务、创新药研发服务合同的执 行周期较长。在较长的新药研发过程中，存在由于药物研究未能达到预期效果、 临床研究失败、客户研究方向改变等因素，公司所签署的服务合同存在延期、 甚至终止的风险。此 ...

博济医药科技股份有限公司 2021 年第三季度报告 □ 是 √ 否 证券代码：300404 证券简称：博济医药 公告编号：2021-085 博济医药科技股份有限公司 2021 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信 息的真实、准确、完整。 3.第三季度报告是否经过审计 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 本报告期比上年同期增 | 年初至报告期末 | 年初至报告期末比上年 | | --- | --- | --- | --- | --- | | | | 减 | | 同期增减 | | 营业收入（元） | 94,026,593.42 | 40.47% | 214,793,258.50 | 21.36% ...

广州博济医药生物技术股份有限公司 2021 年半年度报告全文 广州博济医药生物技术股份有限公司 2021 年半年度报告 2021 年 08 月 1 广州博济医药生物技术股份有限公司 2021 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别 和连带的法律责任。 公司负责人王廷春、主管会计工作负责人欧秀清及会计机构负责人(会计主 管人员)欧秀清声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 详见第三节"管理层讨论与分析"第十点"公司面临的风险和应对措施"。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | 第一节 | 重要提示、目录和释义 2 | | --- | --- | | 第二节 | 公司简介和主要财务指标 7 | | 第三节 | 管理层讨论与分析 10 | | 第四节 | 公司治理 24 | | 第五节 | 环境与社会责任 26 | | 第六节 | 重要事项 27 | | 第七节 | 股份变动及股东情况 33 ...

广州博济医药生物技术股份有限公司 2021 年第一季度报告全文 广州博济医药生物技术股份有限公司 2021 年第一季度报告 2021 年 04 月 1 广州博济医药生物技术股份有限公司 2021 年第一季度报告全文 第一节 重要提示 所有董事均已出席了审议本次季报的董事会会议。 公司负责人王廷春、主管会计工作负责人欧秀清及会计机构负责人(会计主 管人员)欧秀清声明：保证季度报告中财务报表的真实、准确、完整。 2 广州博济医药生物技术股份有限公司 2021 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 55,245,275.36 | 20,818,697.66 | 165.36% | | 归属于上市公司股东的净利润（元） | 7,369,156.02 | -5,863,094.83 | 225.69% | | 归属于上市公司股东的扣除非经常性损 益的净利润（元） | 2,880,893.96 ...

Financial Performance - The company reported a total revenue of 226,619,451, with no cash dividends or bonus shares distributed to shareholders[6]. - The company's operating revenue for 2020 was RMB 260,468,434.47, an increase of 16.25% compared to RMB 224,064,704.39 in 2019[19]. - The net profit attributable to shareholders for 2020 was RMB 16,988,641.81, representing a significant increase of 157.69% from RMB 6,592,620.34 in the previous year[19]. - The net profit after deducting non-recurring gains and losses was RMB 9,855,541.21, up 436.39% from RMB 1,837,396.93 in 2019[19]. - The net cash flow from operating activities reached RMB 97,067,618.03, a remarkable increase of 112,933.87% compared to RMB 85,874.81 in 2019[19]. - The total assets at the end of 2020 were RMB 749,631,868.84, an 18.41% increase from RMB 633,081,946.60 at the end of 2019[19]. - The net assets attributable to shareholders increased by 5.11% to RMB 444,239,449.04 from RMB 422,651,741.36 in 2019[19]. - The basic earnings per share for 2020 was RMB 0.0751, a 157.19% increase from RMB 0.0292 in 2019[19]. - The diluted earnings per share for 2020 was RMB 0.0746, reflecting a 157.24% increase from RMB 0.0290 in the previous year[19]. - The company reported a total of RMB 8,568,324.18 in government subsidies, which was an increase from RMB 4,621,895.60 in 2019[25]. Business Strategy and Development - The company plans to leverage its unique "one-stop" service advantage to adjust its business structure and development direction in response to policy changes in the new drug approval process[4]. - The company aims to enhance its risk resistance by developing innovative drug clinical services and preclinical services, capitalizing on its industry experience and talent[4]. - The company is expanding its business into preclinical research services and CDMO services, facing potential risks due to competition and lack of experience in these areas[6]. - The company emphasizes the importance of internal management and integration to mitigate risks associated with its expanding business scale[6]. - The company plans to strengthen internal training and talent reserves to adapt to changing policies and enhance operational efficiency[4]. - The company is actively developing innovative drug projects, including a ketone sugar kinase inhibitor, which has entered the CMC pharmaceutical research phase[56]. - The company is focusing on developing clinical research services for medical devices and diagnostic formulations to broaden its service offerings[104]. - The company plans to enhance its GLP drug evaluation center's business capabilities to better serve clients[105]. - The company intends to accelerate international expansion through acquisitions of overseas clinical CRO companies[105]. Market Competition and Risks - The rapid growth of domestic CRO companies has intensified market competition, prompting the company to improve its marketing and service levels[5]. - The company acknowledges the risk of contract execution delays due to the complex nature of new drug development, which may lead to budget management challenges[5]. - The company faces risks related to contract execution, including potential delays and cost overruns due to the long duration of drug development projects[108]. - The company has established specific responsibility models in contracts to address potential delays and associated penalties[5]. - The company is cautious in evaluating project execution difficulties before undertaking new projects to mitigate risks associated with new business expansions[111]. - The company has faced management risks due to the expansion of its operational scale and business scope, prompting efforts to enhance internal management and operational efficiency[111]. Research and Development - The company has developed multiple research platforms for traditional Chinese medicine and chemical drugs, enhancing its R&D capabilities[81]. - The company has established a comprehensive preclinical "one-stop" service research system, integrating process, quality, efficacy, pharmacokinetics, and toxicology evaluations[47]. - The company has completed multiple pharmacological and toxicological evaluations for its self-developed projects, including CRAT, ASP, and RUN[83]. - The company aims to obtain 1-2 new drug clinical approval documents annually to enhance its independent research and development capabilities[105]. - The company is conducting clinical research for a new drug targeting drug-resistant lung cancer, with an IND application submitted to the FDA[82]. Shareholder and Financial Management - The company has not proposed any cash dividends, stock bonuses, or capital reserve transfers for the 2020 fiscal year, opting to retain earnings for future investments[117]. - The company has committed to maintaining shareholder interests by not distributing dividends while planning for significant future expenditures[120]. - The company reported a cash dividend of RMB 226,619,451.00 for the year, with a total distributable profit of RMB 112,158,270.72, resulting in a cash dividend ratio of 0.00%[116]. - The company has fulfilled all commitments made by actual controllers and shareholders during the reporting period[122]. - The company has established a commitment to not transfer more than 25% of shares held during the tenure of directors and senior management[122]. - The company has ensured compliance with share transfer commitments to avoid changes in control and ensure long-term stability[124]. Corporate Governance and Compliance - The company emphasizes compliance with laws and regulations, ensuring the protection of stakeholders' rights, including suppliers and creditors[168]. - The company has made commitments to conduct related party transactions under fair and normal commercial conditions[124]. - The company has ensured strict compliance with commitments made by its controlling shareholders to avoid conflicts of interest[126]. - The company has stated that it will provide supplementary commitments in accordance with the latest regulations from securities regulatory agencies if necessary[128]. Subsidiaries and Investments - The company established several new subsidiaries, including Shenzhen Borui Pharmaceutical Technology Co., Ltd. and Jiangxi Bokang Pharmaceutical Technology Co., Ltd., which were included in the consolidated financial statements[137]. - The company participated in a new drug industry investment fund, with the controlling shareholder investing 37 million in the fund[149]. - The company’s wholly-owned subsidiary invested 9 million in the establishment of the Ganjiang New Area Boqu Investment Management Partnership[150]. - The company’s subsidiary, Guangzhou Boji Biological Pharmaceutical Technology Park Co., Ltd., increased its registered capital from 115 million RMB to 121.571 million RMB, with the company's shareholding reduced from 100% to 94.59%[177]. Stock Options and Share Capital - The company completed the first exercise period of its 2019 stock option incentive plan, with 980,655 options available for exercise[142]. - The company approved a new stock option incentive plan for 2020, granting 2.5 million options to 74 eligible participants[144]. - The total number of shares increased from 173,342,000 to 226,619,451 due to the implementation of the 2019 stock option incentive plan and capital reserve conversion[181]. - The company distributed a cash dividend of RMB 0.1 per 10 shares, totaling RMB 1,733,420, and converted 52,296,796 shares from capital reserves[185].

广州博济医药生物技术股份有限公司 2020 年第三季度报告全文 广州博济医药生物技术股份有限公司 2020 年第三季度报告 2020 年 10 月 1 广州博济医药生物技术股份有限公司 2020 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人王廷春、主管会计工作负责人欧秀清及会计机构负责人(会计主 管人员)欧秀清声明：保证季度报告中财务报表的真实、准确、完整。 2 广州博济医药生物技术股份有限公司 2020 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 710,955,847.92 | | 633,081,946.60 | 12.30% | | 归属于上市公司股东的净资产（元 ...

Financial Performance - The company's operating revenue for the first half of 2020 was CNY 110,045,597.78, representing a 17.93% increase compared to CNY 93,316,182.27 in the same period last year[18]. - The net profit attributable to shareholders of the listed company reached CNY 11,874,953.42, a significant increase of 303.23% from CNY 2,944,975.71 in the previous year[18]. - The net profit after deducting non-recurring gains and losses was CNY 8,991,567.52, up 581.16% from CNY 1,320,038.74 in the same period last year[18]. - The net cash flow from operating activities was CNY 44,226,652.47, an increase of 526.31% compared to CNY 7,061,413.83 in the previous year[18]. - Basic earnings per share increased to CNY 0.0526, a rise of 301.53% from CNY 0.0131 in the previous year[18]. - Total operating revenue for the first half of 2020 reached ¥110,045,597.78, an increase of 17.9% compared to ¥93,316,182.27 in the first half of 2019[153]. - Net profit for the first half of 2020 was ¥14,866,119.67, a significant increase of 354.5% from ¥3,272,443.07 in the same period last year[155]. - The total comprehensive income for the first half of 2020 was ¥15,080,552.18, compared to ¥3,299,938.46 in the same period last year, reflecting a growth of 356.5%[156]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 712,113,224.44, reflecting a 12.48% increase from CNY 633,081,946.60 at the end of the previous year[18]. - The total liabilities increased to CNY 229,731,499.54 from CNY 177,003,294.01, indicating a rise of approximately 29.8%[147]. - The company's total assets at the end of the first half of 2020 were CNY 450.88 million, compared to CNY 422.84 million at the end of the previous year[174]. - The total liabilities at the end of the period were approximately 6,957 million yuan, indicating a manageable debt level[170]. Cash Flow - The net cash flow from operating activities for the first half of 2020 was CNY 44,226,652.47, a significant increase from CNY 7,061,413.83 in the same period of 2019, representing a growth of approximately 527%[162]. - Cash inflow from financing activities totaled CNY 49,966,715.62, a substantial increase from CNY 1,356,628.50 in the first half of 2019[163]. - The ending balance of cash and cash equivalents increased to CNY 96,276,582.68 from CNY 69,841,125.50, representing a growth of about 37.9%[163]. Research and Development - The company is focusing on the development of new drugs and generics, leveraging its technical expertise and industry experience[27]. - The company has provided clinical research services for over 800 projects, helping clients obtain more than 60 new drug certificates and approximately 80 production approvals[36]. - The company’s R&D investment increased by 46.37% to ¥10,737,338.09, indicating a strong commitment to innovation[52]. - The company has established five major R&D service platforms, significantly enhancing its capabilities in preclinical research services[40]. Market Position and Strategy - The company operates as a professional CRO service provider, offering a full range of services including preclinical research, clinical research, and CDMO services[25]. - The global CRO market size reached $57.8 billion in 2018, with a projected CAGR of 10.47% from 2018 to 2023, expected to reach $95.1 billion[29]. - The domestic CRO market size was approximately $5.8 billion in 2018, with a projected CAGR of 29.6% from 2018 to 2023, expected to reach $21.4 billion[30]. - The company is one of the few CROs in China capable of providing full-process "one-stop" services for new drug development[34]. Governance and Compliance - All directors attended the board meeting to review this report, ensuring comprehensive oversight[4]. - The financial report was approved by the board of directors on August 26, 2020[182]. - The company has not engaged in any derivative investments or entrusted loans during the reporting period[68][69]. Risks and Challenges - The company faces risks related to policy changes in the new drug research industry, which could impact its business operations and revenue[73]. - The company is facing increased market competition due to the rapid growth of domestic CRO companies, which necessitates improved marketing and service levels[75]. - The company has implemented measures to mitigate risks associated with long-term contract execution in new drug development[74]. Shareholder Information - The number of shareholders holding more than 5% of ordinary shares includes Wang Tingchun with 35.57% and Zhao Lingli with 8.87%[125]. - The total number of ordinary shareholders at the end of the reporting period was 10,096[125]. - The company has implemented a stock option incentive plan, with the first exercise period completed in 2019[120]. Miscellaneous - The company has not engaged in any poverty alleviation initiatives during the reporting period and has no plans for future initiatives[107]. - The company has not conducted any major litigation or arbitration matters during the reporting period[85]. - The company has not received any penalties or corrective actions during the reporting period[87].

广州博济医药生物技术股份有限公司 2020 年第一季度报告全文 广州博济医药生物技术股份有限公司 公司负责人王廷春、主管会计工作负责人欧秀清及会计机构负责人(会计主 管人员)庞咏昕声明：保证季度报告中财务报表的真实、准确、完整。 2 广州博济医药生物技术股份有限公司 2020 年第一季度报告全文 第二节 公司基本情况 2020 年第一季度报告 2020 年 04 月 1 广州博济医药生物技术股份有限公司 2020 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业总收入（元） | 20,818,697.66 | 36,303,568.42 | -42.65% | | 归属于上市公司股东的净利润（元） | -5,863, ...

Dividend Distribution - The company plans to distribute a cash dividend of 0.1 yuan per 10 shares and a capital reserve increase of 3 shares per 10 shares based on a base of 173,342,000 shares[6]. - A cash dividend of RMB 0.1 per share (totaling RMB 1,733,420) will be distributed, with a capital reserve conversion of 3 shares for every 10 shares held[113]. - The cash dividend payout ratio for 2019 was 26.29% of the net profit attributable to shareholders[120]. - The cash dividend payout ratio for 2018 was 27.15% of the net profit attributable to shareholders[120]. - The total cash dividends distributed in 2019 amounted to RMB 1,733,420.00, while the total for 2018 was RMB 2,008,762.50[120]. - In 2015, the company distributed a cash dividend of RMB 0.50 per 10 shares, totaling RMB 6,667,000.00[116]. - No cash dividends were distributed for the years 2016 and 2017, nor were there any stock bonuses or capital reserve transfers[116][117]. - In 2018, the company distributed a cash dividend of RMB 0.15 per 10 shares, totaling RMB 2,008,762.50, and issued 40,175,250 bonus shares[118]. - For 2019, the proposed cash dividend was RMB 0.10 per 10 shares, totaling RMB 1,733,420.00, along with a transfer of 52,002,600 bonus shares[118]. Financial Performance - The company's operating revenue for 2019 was RMB 224,064,704.39, representing a 30.24% increase compared to RMB 172,042,840.49 in 2018[19]. - The net profit attributable to shareholders for 2019 was RMB 6,592,620.34, a decrease of 10.91% from RMB 7,399,910.67 in the previous year[19]. - The net profit after deducting non-recurring gains and losses was RMB 1,837,396.93, down 52.94% from RMB 3,904,677.45 in 2018[19]. - The net cash flow from operating activities was RMB 85,874.81, a significant decline of 99.68% compared to RMB 27,059,863.81 in the previous year[19]. - The total assets at the end of 2019 were RMB 633,081,946.60, an increase of 4.47% from RMB 606,022,667.36 at the end of 2018[19]. - The net assets attributable to shareholders at the end of 2019 were RMB 422,651,741.36, up 2.45% from RMB 412,547,766.99 in 2018[19]. - The company reported a basic earnings per share of RMB 0.0380, down 11.01% from RMB 0.0427 in 2018[19]. - The company achieved total revenue of ¥224,064,704.39 in 2019, representing a year-on-year growth of 30.24%[54]. - The net profit attributable to the parent company was ¥6,592,620.34, a decrease of 10.91% compared to the previous year[54]. Business Strategy and Development - The company aims to enhance its risk resistance by developing innovative drug clinical services and preclinical services, leveraging its industry experience and talent advantages[4]. - The company is focusing on developing new business areas such as preclinical research services and CDMO services, facing potential challenges due to existing competitive players in the market[6]. - The company is committed to adjusting its business structure and development direction in response to changes in drug approval policies by NMPA[4]. - The company aims to meet customer needs and accelerate drug development processes to benefit patient health[28]. - The company is focusing on establishing partnerships with multinational pharmaceutical companies for international multi-center clinical research services[102]. - The company plans to invest in healthcare product R&D and pursue mergers and acquisitions to enhance its industry layout and core competitiveness[104]. - The company will continue to develop its CDMO services and expand its business chain in the R&D and production service areas[104]. - The company aims to integrate its services from drug research to production, establishing a one-stop CRO service model[101]. - The company plans to focus on the CRO industry, aiming to develop a comprehensive new drug research platform over the next three to five years[101]. Risk Management - The company acknowledges the risk of contract execution delays due to the complexity of new drug development, which may lead to budget management challenges and potential cost overruns[5]. - The company has established a risk-sharing mechanism in contracts to address potential losses due to unforeseen circumstances during the execution of long-term projects[5]. - The company recognizes the need for careful project evaluation and strict process management to minimize project delays and associated penalties[5]. - The company anticipates potential risks from policy changes affecting new drug approvals and will adjust its business structure accordingly[105]. - The company is enhancing its management capabilities to mitigate risks associated with expanding its operational scale and business scope[108]. Market Trends and Competition - The rapid growth of domestic CRO companies has intensified competition in the pharmaceutical R&D outsourcing industry, necessitating improved marketing and service levels[5]. - The global CRO industry market size reached $57.8 billion in 2018, with a projected growth to $95.1 billion by 2023, reflecting a CAGR of 10.47% from 2018 to 2023[32]. - The domestic CRO market size was approximately $5.8 billion in 2018, with expectations to grow to $21.4 billion by 2023, indicating a CAGR of 29.6% during the same period[33]. - The CRO industry in China is entering a golden era, driven by the shift of global pharmaceutical outsourcing orders to the Asia-Pacific region and the cost advantages from local engineering talent[33]. Operational Efficiency - The company emphasizes the importance of internal management and integration to improve operational efficiency as it scales its business[6]. - The company has developed a nationwide service network, facilitating high-frequency monitoring of clinical research processes[45]. - The company has implemented a standardized quality control system, improving the reliability and efficiency of clinical research services[42]. - The company aims to expand its clinical research service network and enhance quality control to solidify its competitive edge in the clinical research sector[102]. Research and Development - The company has engaged in some preclinical independent research and technology transformation services based on market trends and technical expertise[28]. - The company has developed multiple new drug and generic drug projects through independent research, leveraging its technical expertise and market trends[30]. - The company is conducting IND research for the targeted therapy drug RUNNOR9591 for drug-resistant lung cancer, which has received clinical research permission[78]. - The company has made significant advancements in inhalation formulations, completing efficacy studies for asthma treatment nebulizers[79]. - Research and development expenses increased by 35.56% to CNY 18,279,480.95, reflecting the company's increased investment in R&D[76]. - The company invested approximately ¥18.28 million in R&D in 2019, representing 8.16% of its operating revenue, an increase from 7.84% in 2018[81]. Subsidiaries and Investments - The company established a new wholly-owned subsidiary, Guangdong Guangji Investment Co., Ltd., during the reporting period[71]. - The company established a joint venture, Shenzhen Chenji Pharmaceutical Technology Co., Ltd., with a registered capital of RMB 30 million, in which the company holds a 10% stake[168]. - The company completed a capital increase for its subsidiary, Guangzhou Boji Biomedical Technology Park Co., Ltd., with the registered capital increasing from 112 million RMB to 121.57 million RMB, reducing the company's ownership from 100% to 94.59%[166]. - The company invested in establishing a new subsidiary, Xinxiang Boji Pharmaceutical Technology Co., Ltd., with a registered capital of 10 million RMB, of which the company contributed 8 million RMB (80%)[166]. Management and Governance - The company has maintained a stable management structure with no significant turnover in key positions over the past year[200]. - The management team includes 10 members, with a mix of roles including independent directors and supervisors[198]. - The average age of the senior management team is approximately 47 years, indicating a relatively experienced leadership[198]. - Wang Tingchun serves as both the chairman and general manager of the company[190]. - The company appointed Wei Fangqun as the new Secretary of the Board on October 28, 2019, following the resignation of Han Yuping[200].